Struggling Ottawa medical device firm Annidis (TSX-V: RHA) said it shipped 15 units of its eye-care imaging technology to its Chinese distribution partner and major shareholder during the second quarter, leading to a dramatic jump in revenues.
The company recorded $786,279 in revenue, up 476 per cent from a year earlier when it failed to make a sale in the quarter.
Annidis also slashed its operating expenses by 27 per cent in the quarter by reducing R&D spending. Combined with the higher sales, the company reduced its net loss to $698,261 for the quarter, an improvement on the $1.29 million loss it recorded a year earlier.
OBJ360 (Sponsored)
AI notetaking for meetings? It could cost you if you don’t do your legal due diligence
We’ve all been there: You hop on a video call and see that, along with your fellow meeting attendees, AI notetaking software is also there, recording, transcribing, and diligently listening
Minto’s Metro Towns at Anthem in Barrhaven & Parkside in Kanata offer attainable home ownership
Guided by the needs of homeowners, Minto has been building new homes and master-planned communities across Canada and the USA for 70 years. To ensure the best quality of life
Earlier this year, the company’s auditors expressed concern about the firm’s ability to continue operating amid its mounting debt.
Annidis’ stock price was flat at one cent on the TSX Venture Exchange on Monday.
